Abstract
The disappearance of methotrexate (MTX) from the serum after an intravenous bolus injection and intravenous infusion was studied over 24 hours in eight and four patients respectively. Probenecid given at the same time as the bolus injection delayed the disappearance of MTX from the serum and resulted in enhanced concentrations throughout the 24 hours studied. At 24 hours the mean concentration was four times higher than in patients not given probenecid. Overall serum concentrations were even greater than those in patients who had received MTX by intravenous infusion. We suggest that smaller doses of MTX may be given and treatment costs thereby reduced if probenecid is given in addition.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aherne G. W., Piall E. M., Marks V. Development and application of a radioimmunoassay for methotrexate. Br J Cancer. 1977 Nov;36(5):608–617. doi: 10.1038/bjc.1977.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bourke R. S., Chheda G., Bremer A., Watanabe O., Tower D. B. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res. 1975 Jan;35(1):110–116. [PubMed] [Google Scholar]
- EICKHOFF T. C., KISLAK J. W., FINLAND M. SODIUM AMPICILLIN: ABSORPTION AND EXCRETION OF INTRAMUSCULAR AND INTRAVENOUS DOSES IN NORMAL YOUNG MEN. Am J Med Sci. 1965 Feb;249:163–171. [PubMed] [Google Scholar]
- Henderson E. S., Adamson R. H., Oliverio V. T. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 1965 Aug;25(7):1018–1024. [PubMed] [Google Scholar]
- Homeida M., Roberts C., Branch R. A. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man. Clin Pharmacol Ther. 1977 Oct;22(4):402–409. doi: 10.1002/cpt1977224402. [DOI] [PubMed] [Google Scholar]
- Hryniuk W. M., Bertino J. R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest. 1969 Nov;48(11):2140–2155. doi: 10.1172/JCI106181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huffman D. H., Wan S. H., Azarnoff D. L., Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):572–579. doi: 10.1002/cpt1973144part1572. [DOI] [PubMed] [Google Scholar]
- Liegler D. G., Henderson E. S., Hahn M. A., Oliverio V. T. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther. 1969 Nov-Dec;10(6):849–857. doi: 10.1002/cpt1969106849. [DOI] [PubMed] [Google Scholar]
- Shapiro W. R., Young D. F., Mehta B. M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975 Jul 24;293(4):161–166. doi: 10.1056/NEJM197507242930402. [DOI] [PubMed] [Google Scholar]
- Skeith M. D., Simkin P. A., Healey L. A. The renal excretion of indomethacin and its inhibition by probenecid. Clin Pharmacol Ther. 1968 Jan-Feb;9(1):89–93. doi: 10.1002/cpt19689189. [DOI] [PubMed] [Google Scholar]